Unity Biotechnology Company

Unity Biotechnology finds solutions against age-related diseases, such as vision loss and cognitive decline, cause considerable economic, personal, and societal burdens for individuals, their families, and broader communities. By targeting age-related diseases, we believe that UNITY can treat these diseases, as well as contain healthcare costs and lessen the emotional and societal burden that comes with an aging population.

Last Funding Type: Series C
Total Funding: 210.6M
Last Funding Date: Mar 19, 2018
Funding Status: Series C
Number Of Exists: 51-100
Employee Number: 51-100
Estimated Revenue: $10M to $50M
Technology: Geroscience
Investors Number: 23
Founded Date: 2009
Headquarters: Brisbane, California, United States
Industry: Drug Development, Gene therapy
Investor Type: IPO